Core Viewpoint - The article emphasizes the importance of investing in defensive stocks amid recent market volatility, highlighting five specific stocks that are well-positioned for stability and growth in uncertain economic conditions [2][4][5]. Group 1: Market Conditions - U.S. stock markets experienced significant volatility in March due to concerns over the sustainability of the AI trade, ongoing geopolitical tensions, rising crude oil and gas prices, inflation expectations, and uncertainty regarding the Federal Reserve's interest rate policy [2]. - The Nasdaq Composite and Dow are in correction territory, trading below 10% from recent highs, while the S&P 500 has recorded its fifth consecutive weekly decline, trading below 8.7% from its recent peak [3]. Group 2: Stock Selection Criteria - Investment in defensive stocks is recommended to safeguard portfolio returns in the near term, focusing on sectors such as utilities, consumer staples, and healthcare [4]. - Stocks selected should be low-beta (beta >0<1) and regularly pay dividends [4]. Group 3: Featured Stocks - **Duke Energy Corp. (DUK)**: Plans to invest $103 billion from 2026-2030 to enhance its grid and expand renewable energy initiatives. DUK has a revenue growth rate of 3.3% and earnings growth rate of 6.3% for the current year, with a dividend yield of 3.28% and a beta of 0.50 [6][10][11]. - **Entergy Corp. (ETR)**: Aims to invest $41 billion from 2026-2029 for infrastructure upgrades and renewable expansion. ETR has a revenue growth rate of 6.8% and earnings growth rate of 12.8% for the current year, with a dividend yield of 2.33% and a beta of 0.64 [12][13]. - **Constellation Brands Inc. (STZ)**: Successfully transitioning to premium brands, with a revenue growth rate of 1.5% and earnings growth rate of 6.5% for the current year, alongside a dividend yield of 2.69% and a beta of 0.44 [14][16]. - **The Coca-Cola Co. (KO)**: Benefits from strong organic revenue growth and effective pricing strategies, with a revenue growth rate of 3.2% and earnings growth rate of 8% for the current year, a dividend yield of 2.80% and a beta of 0.35 [17][19]. - **Johnson & Johnson (JNJ)**: The Innovative Medicine unit shows growth despite exclusivity loss, with a revenue growth rate of 6.6% and earnings growth rate of 7% for the current year, a dividend yield of 2.16% and a beta of 0.34 [20][22].

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts Proactive uses images sourced from Shutterstock Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current levels. In a note to clients, analysts highlighted the company’s position in the emerging field of psychedelic medicine for mental health. “Recently, several psychedelic companies ha ...

Core Insights - Johnson & Johnson's stock has shown strong performance, remaining above its 50-day and 200-day simple moving averages for over eight months, indicating sustained investor confidence [1] - The stock formed a "golden cross" in July, suggesting a potential for a prolonged bullish trend, supported by improving business performance [1] Sales and Earnings Growth - J&J's share price performance is driven by steady growth in sales and earnings, particularly from the Innovative Medicine and MedTech segments, with an optimistic outlook for 2026 [2] - The Innovative Medicine segment saw a 4.1% organic sales growth in 2025, despite the loss of exclusivity for Stelara, with key drugs like Darzalex, Erleada, and Tremfya contributing significantly [4][5] - The segment achieved over $60 billion in full-year sales in 2025, with 13 brands growing in double digits [5] Pipeline and R&D Investments - J&J invested over $32 billion in R&D and M&A in 2025, including acquisitions that enhance its product portfolio [10] - Significant pipeline advancements were made in 2025, with new product approvals expected to drive growth in 2026 [11][12] - J&J believes that several new products have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, and Imaavy [14] MedTech Segment Performance - The MedTech segment improved sales by 4.3% on an organic basis in 2025, driven by acquisitions and advancements in various product lines [15] - J&J anticipates better growth in the MedTech business in 2026, despite facing challenges in the Chinese market due to government cost containment efforts [16][17] Challenges and Risks - The loss of U.S. patent exclusivity for Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [18][19] - J&J faces over 74,000 lawsuits related to its talc-based products, which could pose significant legal and financial challenges [21][22] Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 46.2% over the past year compared to a 7.5% increase in the industry [23] - The stock is currently trading at a price/earnings ratio of 20.05, higher than the industry average of 16.69, indicating a slightly expensive valuation [27] Future Outlook - The Zacks Consensus Estimate for 2026 earnings has increased, reflecting positive sentiment around J&J's growth prospects [30] - J&J aims to generate around $100 billion in revenues in 2026, with expectations for sales growth in both segments to be higher than in 2025 [34] - Despite facing headwinds, J&J remains confident in navigating challenges and maintaining strong momentum [34][35]

Core Insights - Neuronetics reported strong growth in the fourth quarter of 2025, with total revenue reaching $41.8 million, an 86% increase year-over-year, primarily due to the inclusion of Greenbrook operations [12] - The company is focused on building a vertically integrated mental health company post-Greenbrook acquisition, combining technology and clinical infrastructure to enhance patient access to treatment [5][6] - Neuronetics is implementing various operational improvements and strategic initiatives to drive growth in its NeuroStar TMS systems and Greenbrook clinics [19][20] Financial Performance - Fourth-quarter total revenue was $41.8 million, up 86% year-over-year, with adjusted pro forma revenue increasing 23% [12] - NeuroStar revenue for the quarter was $18.3 million, representing 9% growth year-over-year, while U.S. system revenue was $4.4 million, up 15% [13] - Clinic revenue reached $23.5 million, reflecting 37% adjusted pro forma growth, driven by increased treatments across NeuroStar TMS and Spravato [14] Operational Developments - The rollout of Spravato is nearly complete, with 84 clinics providing the treatment, and total treatment volume across Spravato and TMS rose 18% year-over-year in Q4 [1] - Management is standardizing operations across the clinic network, including deploying tablet kiosks for streamlined check-in and piloting a patient portal for digital intake [6] - The BetterMe Provider program ended 2025 with over 420 active sites, connecting more than 66,000 patients with BMP providers [8] Leadership and Strategic Direction - Dan Reuvers has been appointed as the new president and CEO, effective March 23, 2026, succeeding Keith Sullivan [6][4] - The company is focused on expanding customer acquisition models for NeuroStar TMS systems and increasing demand for depression treatments at Greenbrook clinics [19] - Neuronetics is collaborating with Compass Pathways on COMP360 psilocybin for treatment-resistant depression, with plans for an NDA submission [20][21] Cash Flow and Future Outlook - Total cash at the end of 2025 was $34.1 million, with positive cash flow from operations of $0.9 million in Q4 [16] - For 2026, the company projects total revenue between $160 million and $166 million, with expected growth in the clinic business in the double digits [18] - Operating cash flow is expected to be negative $13 million to negative $17 million for the full year, with improvements anticipated in the second half [18]

Neuronetics (NasdaqGM:STIM) Q4 2025 Earnings call March 17, 2026 08:30 AM ET Company ParticipantsAdam Maeder - Managing Director, Equity ResearchCory Anderson - CTODaniel Stauder - Director, Equity ResearchKeith Sullivan - President, and CEOMark Klausner - Managing PartnerSteven Pfanstiel - EVP, CFO, and TreasurerConference Call ParticipantsWilliam Plovanic - Managing Director, Equity Research Medical Technology AnalystOperatorLadies and gentlemen, thank you for standing by, and welcome to the Neuronetics R ...

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Gross margin was 52% in Q4 2025, down from 66% in the prior year, due to the inclusion of Greenbrook's lower-margin clinic business [19] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] Business Line Data and Key Metrics Changes - Total revenue from the NeuroStar business was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a 6% increase on a pro forma basis compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [8] - TRICARE West expanded coverage for TMS therapy to include adolescents aged 15 and older, effective across 26 states [12] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [25][26] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [27][29] - The company is focused on operational efficiencies and expects to reduce operating expenses while driving revenue growth [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive operating cash flow and improve cash conversion through operational efficiencies [20][21] - The company anticipates strong revenue performance in 2026, with guidance for total revenue between $160 million and $166 million, representing over 9% growth versus 2025 [21][22] - Management acknowledged seasonality impacts on revenue, particularly in Q1, and noted weather-related challenges affecting patient access [51][54] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026 [5] - The company achieved positive operating cash flow in Q4 2025, marking a significant milestone [6] Q&A Session Summary Question: Insights on CID investigation in Florida and Michigan - Management confirmed ongoing cooperation with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [35] Question: Differences in patient monitoring for COMP360 - The Chief Technology Officer explained that COMP360 would be administered under a REMS protocol similar to Spravato, with durable treatment effects after one or two doses [38] Question: Cash position after debt payment - Management clarified that the $5 million payment to Perceptive came from non-restricted cash, leaving a comfortable cash balance for operations [41][42] Question: Guidance on clinic growth and Spravato - Management indicated that the majority of growth in the clinic business would come from volume, with Spravato expected to represent a growing share of treatment volume [46][47] Question: Integration of COMP360 into existing infrastructure - Management stated that the existing infrastructure and staff at Greenbrook clinics are well-prepared to administer COMP360 treatments [65]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - EBITDA for Q4 2025 was negative $4.3 million, an improvement from negative $11 million in the prior year [20] - Cash provided by operations in Q4 was positive $0.9 million, marking a significant improvement from negative cash flow earlier in the year [21] Business Line Data and Key Metrics Changes - NeuroStar business revenue, including system and treatment session revenue, was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a pro forma increase of 6% compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [9] - The expansion of TRICARE West coverage for TMS therapy to include adolescents aged 15 and older is a significant development for military families [13] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [26][28] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [28][29] - The company is focused on operational efficiency and expects to reduce operating expenses to less than $100 million by Q4 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive revenue growth and achieve sustainable operating cash flow, with expectations for positive cash flow in the second half of 2026 [25] - The company acknowledges seasonality impacts on revenue, particularly in Q1, and is adapting its strategies accordingly [55][56] - Management highlighted the importance of maintaining strong relationships with primary care physicians and enhancing patient access to treatments [26] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026, indicating a leadership transition [5] - The company has made significant progress in integrating Greenbrook's operations, achieving positive operating cash flow and strengthening its balance sheet [16] Q&A Session Summary Question: Can you provide details on the CID investigation in Florida and Michigan? - Management confirmed that they are cooperating with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [36] Question: What are the profitability and patient monitoring differences for COMP360? - The treatment effect of COMP360 appears durable after one or two doses, and it will be administered under a REMS protocol similar to Spravato [40][42] Question: How did the $5 million payment to Perceptive affect cash position? - The payment did not come from restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [43][44] Question: Can you elaborate on the growth guidance for the clinic and standalone businesses? - Majority of growth in the clinic business is expected to come from volume, with Spravato growth anticipated to be significant in Q1 due to buy-and-bill impacts [50] Question: What are the integration requirements for the Compass collaboration? - The existing infrastructure for Spravato clinics will facilitate the integration of COMP360 treatments, with minimal additional updates needed [68]

Core Insights - The article highlights the performance and outlook of several major stocks, including JPMorgan Chase & Co., Johnson & Johnson, Applied Materials, Inc., and Value Line, Inc. [1][2] Group 1: JPMorgan Chase & Co. (JPM) - JPMorgan's shares have increased by 29.4% over the past year, compared to a 33.5% gain in the Zacks Financial - Investment Bank industry [4] - The bank anticipates a 9% increase in net interest income (NII) for 2026, driven by operational strength, business expansion, and changes in interest rates [5] - JPMorgan plans to invest $19.8 billion in technology initiatives in 2026, although rising costs and macroeconomic challenges may impact asset quality [6] Group 2: Johnson & Johnson (JNJ) - Johnson & Johnson's shares have outperformed the Zacks Large Cap Pharmaceuticals industry, gaining 37.5% over the past six months compared to 21.5% [7] - The Innovative Medicine unit is experiencing growth despite the loss of exclusivity for Stelara, supported by products like Darzalex and Tremfya [9] - The MedTech segment has shown improved operational growth, and J&J expects higher sales growth in both segments for 2026 [9] Group 3: Applied Materials, Inc. (AMAT) - Applied Materials' shares have risen by 135.6% over the past year, outperforming the Zacks Electronics - Semiconductors industry, which gained 68.7% [10] - The company benefits from a rebound in the semiconductor industry, particularly in foundry and logic sectors, along with strong performance in its services and subscription businesses [11] - However, increasing U.S.-China tensions and export restrictions may pose risks to its near-term growth prospects [12] Group 4: Value Line, Inc. (VALU) - Value Line's shares have outperformed the Zacks Financial - Investment Management industry, with a 0.5% increase over the past six months, while the industry declined by 20.8% [13] - The company has a market capitalization of $338.04 million and maintains a debt-free balance sheet, supported by strong cash flows [14] - Despite its stable income profile, Value Line faces challenges such as declining core publishing revenues and customer concentration risk [15]

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, with significant revenue growth driven by its immunology portfolio and steady contributions from its neuroscience segment [1][2]. Neuroscience Segment Performance - The neuroscience segment generated $10.8 billion in revenue for 2025, accounting for approximately 18% of AbbVie's total revenues, reflecting a nearly 20% year-over-year increase [2][8]. - Key products in this segment, including Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, experienced double-digit sales growth, while the newer therapy Vyalev contributed $482 million in sales [2][8]. - For 2026, AbbVie anticipates neuroscience revenues to reach $12.5 billion, indicating a 16% growth from 2025, with expectations for Vyalev to exceed $1 billion in global sales [3][8]. Product Pipeline and Future Growth - AbbVie is preparing to expand its neuroscience portfolio with a new oral therapy for Parkinson's disease, tavapadon, which is currently under FDA review [4]. - If approved, tavapadon could enhance AbbVie's presence in the Parkinson's disease market and strengthen the long-term growth potential of its neuroscience segment [4]. Competitive Landscape - Competitors in the neuroscience space include Biogen and Johnson & Johnson, both of which are also focusing on expanding their neuroscience offerings [5][6]. - Biogen is diversifying its portfolio due to declining revenues in its multiple sclerosis franchise, while Johnson & Johnson continues to grow its neuroscience products through acquisitions and new therapies [5][6]. Valuation and Market Performance - AbbVie shares are currently trading at a price/earnings (P/E) ratio of 15.61, which is below the industry average of 18.26, although above its five-year mean of 13.73 [9]. - The Zacks Consensus Estimate for AbbVie's 2026 EPS has increased from $14.31 to $14.54, indicating positive market sentiment [11].

Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden GH Research PLC (Nasdaq: GHRS) March 2026 2026© GH Research PLC 1 Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC ("GH Research"). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive ...